Compugen (CGEN) Receivables (2009 - 2024)

Compugen (CGEN) posted quarterly Receivables of $5.0 million for Q2 2024, down 91.8% on a QoQ basis from $61.0 million in Q4 2023.

Compugen (CGEN) Receivables (2009 - 2024) Analysis & Trends

Compugen has reported Receivables for 11 years, with the latest figure at $5.0 million in Q2 2024.

Receivables for Q2 2024 came in at $5.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was $5.0 million (changed N/A YoY), and the FY2023 annual result was $61.0 million, changed N/A from the prior year.
Receivables declined to $5.0 million in Q2 2024, from $61.0 million in the prior quarter.
Over five years, Receivables peaked at $61.0 million in Q4 2023 and troughed at $2.0 million in Q4 2020.
A 4-year average of $18.5 million and a median of $5.5 million in 2021 frame the typical range for Receivables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	Compugen	227.88 Mn	136.13 Mn	352,000.00	-

Download Data